ArticleBMC cardiovascular disorders2025
The Role of microRNA-19b, microRNA-21, and microRNA-208a in diagnosis of heart failure.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a fast-growing public health concern that is linked to substantial morbidity and mortality as well as a poor quality of life. There is no specific biomarker that can be used to detect early HF with preserved ejection fraction (EF). MicroRNAs (miRs) are known to be involved in the development of HF.
aimTo investigate the plasma level of miR-19b, miR-21, and miR-208a and their relevance in early diagnosis of HF. SUBJECTS AND
methodsIn this study, 120 participants were divided into four groups: 30 controls in Group I, 30 HF patients with preserved EF in Group II, 30 HF patients with mildly reduced EF (HFmrEF) in Group III, and 30 HF patients with reduced EF (HFrEF) in Group IV. Real-time PCR was used to examine the expression levels of miR-19b, miR-21, and miR-208a, and ELISA was used to assess the NT-proBNP level.
resultsCompared to controls, HF patients' groups exhibited a substantial sequential rise in miR-21 and miR-208a expression (p < 0.001). However, HF patients had considerably lower levels of miR-19b expression compared to controls (p < 0.001). The cutoff value of miR-19b to discriminate HFmrEF from HFpEF was 11.2 (93.3% sensitivity, 86.7% specificity) (p < 0.001). In contrast, miR-21 had a cutoff value of 5.5 (70% sensitivity and 76.7% specificity), and miR-208a had a cutoff point of > 10.3 (93.3% sensitivity and 93.3% specificity).
conclusionMiR-19b, miR-208a and miR-21 could be useful biomarkers with high sensitivity and specificity for early detection of HF and in discrimination between HFmrEF and HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.